MARKET

RTGN

RTGN

RETINALGENIX TECHNOLOGIES INC
OTCMQB
3.540
NaN%
Closed 09:30 02/12 EST
OPEN
--
PREV CLOSE
3.540
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
53.00
52 WEEK LOW
1.600
MARKET CAP
65.86M
P/E (TTM)
-24.3299
1D
5D
1M
3M
1Y
5Y
1D
RetinalGenix Reveals AI Retinal Mapping Links Eye Changes to Neurodegenerative and Metabolic Diseases
Reuters · 01/14 11:01
RetinalGenix Reports on its Science and Mission in Light of New AI-Driven Retinal Mapping Study
Barchart · 01/14 05:01
RetinalGenix announces key mangement changes
Seeking Alpha · 12/09/2025 07:22
RetinalGenix Technologies Names M. Cory Zwerling CFO and Interim COO
Reuters · 12/09/2025 00:43
RETINALGENIX TECHNOLOGIES AGREES TO HIRE M. CORY ZWERLING AS CFO, INTERIM COO
Reuters · 12/09/2025 00:43
RetinalGenix Technologies contracts Seer Bio to advance early detection of neurodegenerative systemic and retinal diseases
Reuters · 10/16/2025 09:01
RetinalGenix Technologies Contracts with Seer Bio to Explore Early Detection of Neurodegenerative, Systemic, and Retinal Diseases
Barchart · 10/16/2025 04:01
RetinalGenix Technologies and RGEN Inc. Announce Strategic Partnership to Revolutionize Early Detection of Neurodegenerative and Retinal Diseases
Reuters · 10/01/2025 10:01
More
About RTGN
RetinalGenix Technologies Inc. is an ophthalmic research and development company seeking to revolutionize early disease detection and improve patient outcomes across multiple disease areas. The Company's proprietary High-Resolution Retinal Imaging and DNA/RNA/GPS Pharmaco-Genetic Mapping technologies are designed to help prevent blindness by detecting initial physiological changes that could indicate future ocular and systemic diseases affecting neurodegenerative, cardiovascular, vascular and metabolic systems, as well as diabetic conditions, Alzheimer’s disease and Parkinson’s disease. Its RetinalCam is an in-home/remote location patient-activated monitoring and imaging device offering real-time communication and alerting system for physicians available 24/7. It is also engaged in the development of its product candidates: RTG-2023 and RTG-2024. RTG-2023 for the treatment of dry age-related macular degeneration (dry AMD). RTG-2024 for the treatment of Alzheimer’s syndrome dementia.

Webull offers RetinalGenix Technologies Inc stock information, including OTCMQB: RTGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RTGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RTGN stock methods without spending real money on the virtual paper trading platform.